


IN THE CLAIMS

Please amend the claims as follows:

1. (Withdrawn) An antibody that specifically binds to a Cav3 isoform or its $\delta 25$ splicing variants thereof.
2. (Withdrawn) The antibody of Claim 1, wherein the Cav3 isoform is a Cav3.2 isoform.
3. (Withdrawn) The antibody of Claim 1, wherein the antibody is a humanized antibody.
4. (Withdrawn) A pharmaceutical composition comprising an antibody of Claim 1 and a pharmaceutically acceptable carrier.
5. (Withdrawn) A method for diagnosing cancer comprising detecting the presence of a Cav3 isoform protein and/or its $\delta 25B$ splice variant in a tissue sample from a patient.
6. (Withdrawn) A method for treating cancer comprising detecting the presence of a Cav3 isoform protein and/or its $\delta 25B$ splice variant in a patient according to Claim 5 and administering to the patient a therapeutically effective amount of an antibody against the Cav3 isoform and/or its $\delta 25B$.
7. (Currently Amended) A method for inducing cytostasis comprising administering to a patient in need thereof a therapeutically effective amount of T type calcium channel selective inhibitor so as to induce cytostasis in said patient.

8. (Original) The method of Claim 7, wherein the T type calcium channel selective inhibitor is a tetrahydronaphthalene derivative of the formula



wherein R^1 is a halogen, R^2 is a lower-alkoxy-lower-alkyl-carbonyloxy, X is a C_2 - C_8 -alkylene, and A is a benzimidazolyl optionally substituted at the N atom with 1 to 12 C atoms in the form of their free bases, their hydrates, or their pharmaceutically usable salts for the treatment, control, and prevention of cancer.

9. (Original) The method of Claim 7, wherein the T type calcium channel selective inhibitor is a mibefradil of the formula (1S,2S)-(2 {[3-(2-benzimidazolyl) propyl] methylamino} ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthylmethoxyacetate dihydrochloride.

10. (Currently Amended) A method of inhibiting cancer cell ~~cell~~ proliferation comprising administering to a patient in need thereof a therapeutically effective amount of mibefradil so as to induce cytostasis in the patient.

Claims 11-12 (Cancelled).

13. (Withdrawn) A method of treating autoimmune diseases comprising administering to a patient in need thereof a therapeutically effective amount of T type calcium channel selective inhibitor.

14. (Withdrawn) A method for preventing graft rejections comprising administering to a patient in need thereof a therapeutically effective amount of T type calcium channel selective inhibitor.

15. (Withdrawn) A method for preventing apoptosis comprising administering to a patient in need thereof a therapeutically effective amount of T type calcium channel selective inhibitor.